Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02421978 · ClinicalTrials.gov registry record

Inflammation-Induced CNS Glutamate During Breast Cancer Treatment

A clinical trial of Breast Cancer, sponsored by Emory University.

Completed
Registry status
98
Enrollment target
1
Study location

NCT02421978 is a study of Breast Cancer that has completed, run by Emory University. The registered enrollment target is 98 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02421978, a study of Breast Cancer, has completed, sponsored by Emory University.

COMPLETED
Registry status
98 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to try and provide data linking the impact of increased inflammatory cytokines as a result of chemotherapy and their relationship with increased levels of CNS glutamate and related behavioral and cognitive consequences in breast cancer patients. The investigators will use neuropsychiatric assessments, blood sampling and Magnetic Resonance Spectroscopy (MRS) to collect study data.

Conditions Studied

Study Locations (1)

Georgia

  • Emory University Department of Psychiatry and Behavioral Sciences - Atlanta

Trial Details

FieldValue
Enrollment Target 98 participants
Start Date 2015-05
Est. Completion 2018-05-29

Sponsor

Emory University

1,208 total trials

What the Registry Record Tells You About NCT02421978

The ClinicalTrials.gov registry entry for NCT02421978 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT02421978 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT02421978 about?

NCT02421978 is a clinical study titled "Inflammation-Induced CNS Glutamate During Breast Cancer Treatment". The purpose of this study is to try and provide data linking the impact of increased inflammatory cytokines as a result of chemotherapy and their relationship with increased levels of CNS glutamate and related behavioral and cognitive consequences in breast cancer patients. The investigators will us...

What is the current status of trial NCT02421978?

This trial is currently completed. The enrollment target is 98 participants. The study started on 2015-05. Estimated completion is 2018-05-29.

What conditions does trial NCT02421978 study?

This clinical trial studies the following conditions: Breast Cancer.

Who is sponsoring clinical trial NCT02421978?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02421978 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.